Summary
India's pharma market is experiencing a significant shift with GLP-1 drugs gaining traction, as evidenced by Mounjaro's 502% sales surge to ₹1,256 crore. This growth is driven by increased awareness of diabetes and obesity treatments, with experts like Abhishek Basumallick remaining positive on the sector due to GLP-1 potential and upcoming patent expiries.